KYTX Logo

Kyverna Therapeutics, Inc. Common Stock (KYTX) Stock Forecast & Price Prediction

Live KYTX Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$3.00

-0.11 (-3.54%)

12 Month Price Forecast For KYTX

$3.00
Current Price
$134.26M
Market Cap
6 Ratings
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings

Distance to KYTX Price Forecasts

+1,233.3%
To High Target of $40.00
+716.7%
To Median Target of $24.50
+100.0%
To Low Target of $6.00

KYTX Price Momentum

-7.4%
1 Week Change
-21.1%
1 Month Change
-90.0%
1 Year Change
-19.8%
Year-to-Date Change
-91.4%
From 52W High of $35.06
0.0%
From 52W Low of $3.00

๐Ÿค” Considering Kyverna (KYTX)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 3:56 AM UTC

KYTX Analyst Ratings & Price Targets

Based on our analysis of 5 Wall Street analysts, KYTX has a consensus that is bullish. The median price target is $24.50, with forecasts ranging from $6.00 to $40.00. Currently, there are 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings.

With KYTX currently trading at $3.00, the median price forecast suggests a 716.7% upside. The most optimistic forecast comes from Michael Ulz at Morgan Stanley, projecting a 1,233.3% upside, while Mitchell Kapoor at HC Wainwright & Co. provides the most conservative target, suggesting a 100.0% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

KYTX Analyst Consensus

5
Buy
1
Hold
0
Sell

KYTX Price Target Range

Low
$6.00
Average
$24.50
High
$40.00
Current: $3.00

Latest KYTX Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for KYTX.

Date Firm Analyst Rating Change Price Target
Nov 20, 2024 HC Wainwright & Co. Mitchell Kapoor Neutral Maintains $6.00
Nov 15, 2024 Wells Fargo Derek Archila Overweight Maintains $24.00
Oct 10, 2024 UBS Trung Huynh Buy Initiates $13.00
Sep 19, 2024 HC Wainwright & Co. Mitchell Kapoor Neutral Reiterates $7.00
Aug 15, 2024 HC Wainwright & Co. Mitchell Kapoor Neutral Maintains $7.00
Jul 31, 2024 JP Morgan Brian Cheng Overweight Maintains $33.00
Jul 16, 2024 HC Wainwright & Co. Mitchell Kapoor Neutral Reiterates $8.00
Jul 3, 2024 HC Wainwright & Co. Mitchell Kapoor Neutral Initiates $8.00
Mar 4, 2024 Morgan Stanley Michael Ulz Overweight Initiates $40.00
Mar 4, 2024 JP Morgan Brian Cheng Overweight Initiates $39.00

Stocks Similar to Kyverna Therapeutics, Inc. Common Stock

The following stocks are similar to Kyverna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Kyverna Therapeutics, Inc. Common Stock (KYTX) Financial Data

Kyverna Therapeutics, Inc. Common Stock has a market capitalization of $134.26M with a P/E ratio of -2.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -59.6%.

Valuation Metrics

Market Cap $134.26M
Enterprise Value $-178,200,576
P/E Ratio -2.0x
PEG Ratio -0.8x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +248.3%
Current Ratio 10.5x
Debt/Equity 3.0x
ROE -59.6%
ROA -35.6%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Kyverna Therapeutics, Inc. Common Stock logo

Kyverna Therapeutics, Inc. Common Stock (KYTX) Company Overview

About Kyverna Therapeutics, Inc. Common Stock

What They Do

Develops cell therapies for autoimmune diseases.

Business Model

Kyverna Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of autologous and allogeneic CAR T-cell therapies. It generates revenue through licensing and collaboration agreements with other biotechnology companies, which support its research and development efforts for various autoimmune diseases.

Additional Information

The company's lead product, KYV-101, is currently in Phase I and II clinical trials for lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis. Additionally, KYV-201 is under development for multiple autoimmune diseases in the preclinical stage. Kyverna was formerly known as BAIT Therapeutics and changed its name in October 2019, highlighting its commitment to innovative therapies in the autoimmune space.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

96

CEO

Mr. Warner Biddle

Country

United States

IPO Year

N/A

Kyverna Therapeutics, Inc. Common Stock (KYTX) Latest News & Analysis

KYTX stock latest news image
Quick Summary

A class action lawsuit has been filed against Kyverna Therapeutics, Inc. (NASDAQ:KYTX) for alleged federal securities law violations related to its February 2024 IPO.

Why It Matters

A class action lawsuit against Kyverna Therapeutics could indicate potential legal and financial risks, impacting investor confidence and stock performance following its IPO.

Source: Accesswire
Market Sentiment: Neutral
KYTX stock latest news image
Quick Summary

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investors who experienced losses may explore recovery options under federal securities laws. More information is available via the provided link.

Why It Matters

The announcement of a potential lawsuit for Kyverna Therapeutics indicates possible legal and financial risks, which may affect stock performance and investor confidence.

Source: Accesswire
Market Sentiment: Neutral
KYTX stock latest news image
Quick Summary

Investors in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) who have incurred losses may explore potential recovery options under federal securities laws. More details are available via the provided link.

Why It Matters

The news indicates potential legal issues for Kyverna Therapeutics, which could affect its stock performance and investor confidence, signaling a need for investors to reassess their holdings.

Source: Accesswire
Market Sentiment: Neutral
KYTX stock latest news image
Quick Summary

Investors in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) who experienced losses may explore potential recovery options under federal securities laws. Further details are available through a provided link.

Why It Matters

A potential lawsuit for Kyverna Therapeutics may indicate underlying issues, affecting stock performance and investor confidence, which could lead to volatility.

Source: Accesswire
Market Sentiment: Neutral
KYTX stock latest news image
Quick Summary

Investors in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) who experienced losses may explore potential recovery options under federal securities laws. More info is available via the provided link.

Why It Matters

A potential lawsuit indicates investor dissatisfaction and possible financial instability for Kyverna Therapeutics, which may affect its stock price and investor sentiment.

Source: Accesswire
Market Sentiment: Neutral
KYTX stock latest news image
Quick Summary

Investors in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) who experienced losses may explore potential recovery options under federal securities laws. More information is available through a specified link.

Why It Matters

A potential lawsuit against Kyverna Therapeutics may indicate problems within the company, affecting stock performance and investor confidence. Legal issues can lead to volatility and loss recovery opportunities.

Source: Accesswire
Market Sentiment: Neutral

Frequently Asked Questions About KYTX Stock

What is Kyverna Therapeutics, Inc. Common Stock's (KYTX) stock forecast for 2025?

Based on our analysis of 5 Wall Street analysts, Kyverna Therapeutics, Inc. Common Stock (KYTX) has a median price target of $24.50. The highest price target is $40.00 and the lowest is $6.00.

Is KYTX stock a good investment in 2025?

According to current analyst ratings, KYTX has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.00. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for KYTX stock?

Wall Street analysts predict KYTX stock could reach $24.50 in the next 12 months. This represents a 716.7% increase from the current price of $3.00. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Kyverna Therapeutics, Inc. Common Stock's business model?

Kyverna Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of autologous and allogeneic CAR T-cell therapies. It generates revenue through licensing and collaboration agreements with other biotechnology companies, which support its research and development efforts for various autoimmune diseases.

What is the highest forecasted price for KYTX Kyverna Therapeutics, Inc. Common Stock?

The highest price target for KYTX is $40.00 from Michael Ulz at Morgan Stanley, which represents a 1,233.3% increase from the current price of $3.00.

What is the lowest forecasted price for KYTX Kyverna Therapeutics, Inc. Common Stock?

The lowest price target for KYTX is $6.00 from Mitchell Kapoor at HC Wainwright & Co., which represents a 100.0% increase from the current price of $3.00.

What is the overall KYTX consensus from analysts for Kyverna Therapeutics, Inc. Common Stock?

The overall analyst consensus for KYTX is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $24.50.

How accurate are KYTX stock price projections?

Stock price projections, including those for Kyverna Therapeutics, Inc. Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.